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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the benefits and harms of calcium and vitamin D supplementation singly or in combination for reducing fractures and
increasing bone mineral density in healthy premenopausal women.
B A C K G R O U N D
Description of the condition
Osteoporosis (OP) is characterized by low bone mineral density
(BMD) and impaired quality of bone, and is considered a major
public health concern worldwide. The main consequence of low
BMD is fragility fractures, mainly at the hip, spine and wrist (NIH
1993). BMD in later life is a function of peak bone mass (the
maximum bone mass attained in a person’s life) and the rate of
subsequent bone loss (Hansen 1991). Premenopausal bone mass
is as important as bone loss in the postmenopausal period for pre-
diction of fracture. Fragility fractures may lead to excess mortality,
morbidity, low quality of life, and chronic pain (Borgström 2013;
Papaioannou 2010).
It is estimated thatOPaffects about 200millionpeopleworldwide,
and 75 million of them are from developed countries (Europe,
Japan and USA) (Kanis 2007). In the year 2000, 9 million new
fragility fractures occurred, including 1.6 million on the hip, 1.7
million in the wrist and1.4 million on the spine (Johnell 2004).
OP prevention is feasible and should be addressed throughout the
life course, improving peak bonemass in childhood and early adult
life and reducing age-related bone loss over adult life.
Description of the intervention
Dietary intake and supplementation therapy options for preven-
tion and treatment of osteoporosis include Calcium and vitamin
D. There are primarily obtained from two sources: food and sup-
plements. Dairy products are a good source of dietary calcium.
Regarding vitamin D, the main source in humans is the synthesis
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in the skin through sun exposure, since vitamin D is only found in
small quantities in certain foods. Calcium supplements are most
commonly available as calcium citrate or calcium carbonate; vita-
min D can be found as ergocalciferol (vitamin D2) and cholecal-
ciferol (vitamin D3). A combination of both nutrients is available
in different doses and presentations. Calcium and vitamin D sup-
plements are also prescribed with anti-osteoporotic medications
as they are thought to have additive effects. Clinical trials have
been conducted in different age groups and populations, in order
to assess the efficacy of this strategy.
There are Cochrane systematic reviews and meta-analyses of cal-
cium and vitamin D supplementation for improving bone min-
eral density in children and postmenopausal women (Shea 2005;
Winzenberg 2006; Winzenberg 2010). Currently, there is no
known effect of calcium supplementation on femoral neck or lum-
bar spine BMD in children, but review authors found a small effect
on total body bone mineral content (BMC) and upper limb BMD
in this population (Winzenberg 2006). However, in their conclu-
sion, the authors stated that the increase in BMD is unlikely to re-
sult in a clinically significant decrease in fracture risk (Winzenberg
2006). Another review showed that vitamin D supplementation
had no effect on BMC, hip BMD and forearm BMD, but there
was a trend to a small effect on lumbar spine BMD. The review
concluded that these results do not support vitamin D supplemen-
tation to improve BMD in healthy children with normal vitamin
D levels (Winzenberg 2010). Studies where the participants had
low mean levels of vitamin D saw an effect of supplementation on
BMD (Winzenberg 2010).
The review of calcium supplementation for postmenopausal
women showed that calcium had a small effect on BMD when
compared to placebo. Calcium reduced rates of bone loss after two
or more years of treatment, but there was no effect seen on fracture
risk (Shea 2005).
There remains some controversy in this field; Murad 2011 argues
that a combination of both nutrients have a beneficial role in
increasing bone density, muscle strength and a reduction of falls
in the elderly. The United States Preventive Services Task Force
(USPSTF), however, states that for primary prevention of fractures
in postmenopausal women, there is some evidence of increased
risk of cardiovascular damage that has led to disagreement about
the balance of the benefits and harms of daily supplementation
with more than 400 IU of vitamin D and more than 1000 mg of
calcium (Moyer 2013).
In a systematic review (Malihi 2016) of the effect of long-term
(> 24 weeks) vitamin D supplementation versus placebo, in both
healthy and in different patient populations (adults aged over 18
years, men and women), the authors reported increased risks of
hypercalcemias (RR = 1.54, 95% confidence interval (CI) 1.09 to
2.18, P = 0.01) and hypercalciuria (RR = 1.64, 95% CI 1.6 to
2.53, P = 0.03). However, in that review, the participants included
a mix of different populations.
How the intervention might work
Calcium and vitamin D are simple and inexpensive interventions
which potentially improve bone health. Calcium is needed for
bone formation and is lost from the body (through urine and the
renal system) each day, and needs to be replaced. Low serum cal-
cium leads to increased parathyroid hormone (PTH) and increased
bone loss. Therefore, maintaining adequate calcium intake is im-
portant. Vitamin D is essential for bone health, and its impact on
bone health in adults is well accepted (IOM 2011). Vitamin D is
integral to calcium homeostasis. It increases intestinal absorption
of calcium. Bones are the main store of calcium in the body; as
age increases intestinal absorption decreases.
In addition to the direct effects on bone, vitamin D has been as-
sociated with muscle strength and prevention of the risk of falls.
As vitamin D receptors are found in different tissues, includ-
ing muscle tissue, their activation leads to muscle protein syn-
thesis. In this way, vitamin D supplements may improve mus-
cle strength, and decrease the risk of falls (Bischoff-Ferrari 2009;
Gupta 2010; Zhu 2010). Authors of a meta-analysis published in
2009 (Bischoff-Ferrari 2009) concluded that daily supplementa-
tion with more than 700 IU of vitamin D reduced the risk of falls
in people over 65 years old (relative risk 0.81, 95% CI 0.71 to
0.92). This review had some heterogeneity in the studies included
in the meta-analysis. However, in a meta-analysis performed by
Murad, vitamin D supplementation had no effect on the risk of
falls, regardless of dose and type of vitamin D used. Neverthe-
less, when vitamin D is co-administered with calcium, there is a
reduction in the risk of falls in the elderly compared to placebo
(odds ratio (OR) 0.83 95%CI 0.72 to 0.93). Heterogeneity was
found across the studies despite using a random-effects model and
subgroup analysis (Murad 2011).
Fracture risk is related to bone strength. Bone strength is con-
tributed to by bone quantity (BMD) and bone quality. Bone qual-
ity takes into account structural and material properties, which
cannot be assessedwithBMD. Structural properties include geom-
etry and microarchitecture; material properties are organization
and composition of mineral and collagen components. It would
be ideal to assess all the components of bone strength in order
to have a better prediction of fracture risk. Nevertheless, BMD
remains an important clinical measurement (Felsenberg 2005).
In addition, increased BMD in the context of other anti-os-
teoporotic treatments correlate with fracture risk reductions
(Hochberg 1999) and BMD has been used as a surrogate out-
come when assessing alternative dosage regimens for bisphospho-
nate (Rizzoli 2002; Winzenberg 2008). According to the Cana-
dian Agency for Drugs and Technologies in Health (CADTH) re-
port, BMD assessed by dual energy X-ray absorptiometry (DXA)
predicts fragility fracture risk with a power of the diagnostic test
(expressed as area under the curve (AUC)) from 0.60 to 0.95. An
AUC close to 1.0 means a perfect test (Dunfield 2007).
DXA will be the ideal method of measuring BMD and BMC in
relevant studies, as it is the reference standard measure that is used
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to define osteoporosis (Lewiecki 2016).
Why it is important to do this review
The effect of calcium and vitamin D on BMD and fractures has
been studied in children and in postmenopausal women, but less
is known about the effects of calcium and vitamin D in pre-
menopausal women. In February 2013, the USPSTF published
a systematic review and meta-analysis of the use of calcium and
vitamin D supplements to prevent fractures in adults. The USP-
STF stated that the evidence at that time was insufficient to as-
sess the benefits and harms for prevention of fractures in pre-
menopausal women (Moyer 2013). Osteoporotic fractures are un-
likely in this age group (premenopausal women) so other clini-
cal variables should be measured, such as BMD and BMC. Exist-
ing systematic reviews have not accounted for more recent studies
(Moyer 2013), and others in process are not yet finished (USPSTF
2016). Other Cochrane reviews in this topic area have focused in
other populations such children or postmenopausal women (Shea
2005; Winzenberg 2006; Winzenberg 2010).
An up-to-date review in this area is important because pre-
menopause is a period where peak bone mass can be potentially
maintained or even improved to prevent fragility fractures in the
future (Shea 2005). Given that calcium and vitamin D are two
important modifiable factors to potentially improve bone density,
it is important to determine the benefits and harms of the differ-
ent doses/combination to maintain or improve BMD and bone
quality in premenopausal women.
This review will be conducted according to the guidelines recom-
mended by Cochrane Musculoskeletal (Ghogomu 2014).
O B J E C T I V E S
To assess the benefits and harms of calcium and vitamin D supple-
mentation singly or in combination for reducing fractures and in-
creasing bone mineral density in healthy premenopausal women.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials (RCTs). Studies may
be reported as full-text or published as abstract only. There will be
no language restriction.
Types of participants
We will include trials in healthy premenopausal women aged 18
to 45 (and studies when the menopausal status is not specified
but the age is reported), with or without vitamin D deficiency or
calcium. Healthy women are defined as women with no known
osteoporosis (OP) or osteopenia and without any chronic disease,
cardiovascular condition, or autoimmune or inflammatory dis-
ease (e.g. rheumatoid arthritis, osteoarthritis, fibromyalgia, multi-
ple sclerosis, systemic lupus erythematosus, diabetes mellitus and
asthma).
We will exclude studies in pregnant and lactating women, in par-
ticipants with coexisting medical conditions and with corticoid
steroid-induced or other secondary causes of osteoporosis. When
studies include also male participants, we will exclude them if in-
formation by sex cannot be extracted separately.
Types of interventions
We will include trials comparing calcium and vitamin D with
placebo, focusing on three comparisons (regardless of type or dose
of supplementation).
1. Calcium versus placebo.
2. Vitamin D versus placebo.
3. Calcium + vitamin D versus placebo.
We will conduct other subgroup analyses if needed (i.e. calcium
plus vitamin D versus vitamin D alone, or calcium alone). We will
exclude trials with a treatment period of less than three months.
We will exclude the following cointerventions of specific anti-os-
teoporosis therapy such as bisphosphonate, hormone replacement
therapy, parathyroid hormone, selective estrogenic receptor mod-
ulators (SERMs), and strontium ranelate.
Types of outcome measures
Major outcomes
1. Total hip BMD.
2. Lumbar spine BMD.
3. Quality of life.
4. Vertebral fractures.
5. Non-vertebral fractures.
6. Withdrawals due to adverse events.
7. Serious adverse events (i.e., hospitalizations, or those
resulting in disability or death).
Minor outcomes
1. We will collect data about all adverse events and all harm
reported.
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Search methods for identification of studies
Electronic searches
We will design a search strategy for the following databases.
• Cochrane Library via Wiley including CENTRAL, and
Database of Reviews of Effects (DARE).
• MEDLINE via Ovid (1946 to present).
• Embase via Ovid (1947 to present).
The electronic search strategy for MEDLINE is outlined in
Appendix 1. We will adapt this search strategy for use with other
databases. We used the ’sensitivity and precision maximising ver-
sion’ filter designed to identify clinical trials described by Lefebvre
2009.
For assessments of adverse effects, we will search the web sites
of the regulatory agencies US Food and Drug Administration-
MedWatch (www.fda.gov/Safety/MedWatch/default.htm), Euro-
pean Medicines Evaluation Agency (www.emea.europa.eu), Aus-
tralian Adverse Drug Reactions Bulletin (www.tga.gov.au/adr/
aadrb.htm), and UK Medicines and Healthcare products Regula-
tory Agency (MHRA) pharmacovigilance and drug safety updates
(www.mhra.gov.uk).
We will also conduct a search of clinicaltrials.gov and the WHO
trials portal (www.who.int/ictrp/en/).
We will search all databases from their inception to the present,
and we will impose no restriction on language of publication.
Searching other resources
Unpublished results
We will search clinical trial registries for unpublished data. To
obtain further information, we will contact the authors of studies
on clinical registers or with results given only in graphic format or
reported only as abstracts. If data are not available after contacting
authors, the study will be described in the evidence table, but we
will not include it in the meta-analysis.
Reference list scanning
We will search the reference lists of other reviews that are related
in terms of the interventions and outcomes, and also search the
reference lists of the included studies of this review.
Handsearching
We will handsearch conference abstract issues of key journals (Os-
teoporosis International, Journal of Bone and Mineral Research,
Calcified Tissue International, Journal of Clinical Endocrinology
and Metabolism, American Journal of Clinical Nutrition, Euro-
pean Journal of Clinical Nutrition, Journal of Nutrition, British
Journal of Nutrition) for the past two years, to identify recent trials
that have not yet been published in full.
We will search for errata or retractions from included studies pub-
lished in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and report the date this was done within the review.
Data collection and analysis
Selection of studies
Two review authors (LM-S and PC) will independently screen ti-
tles and abstracts of all of the potentially relevant studies we iden-
tify as a result of the search, and code them as ’retrieve’ (eligi-
ble or potentially eligible/unclear) or ’do not retrieve’. We will re-
trieve the full-text study reports/publication and two review au-
thors (LM-S and PC) will screen the full text and identify studies
for inclusion, and identify and record reasons for exclusion of the
ineligible studies. We will resolve any disagreement through dis-
cussion or, if required, we will consult a third person (TW). We
will identify and exclude duplicates and collate multiple reports of
the same study so that each study, rather than each report, is the
unit of interest in the review. We will record the selection process
in sufficient detail to complete a PRISMA flow diagram (prisma-
statement.org/PRISMAStatement/Default.aspx) and ’Character-
istics of excluded studies’ table.
Data extraction and management
We will use a data collection form for study characteristics and
outcome data, which has been piloted on at least one study in the
review.One review author (LM-S)will extract study characteristics
from included studies. A second review author (PC) will spot-
check study characteristics for accuracy against the trial report.We
will extract the following study characteristics.
1. Methods: study design, total duration of study, details of any
’run-in’ period, number of study centres and location (country),
study setting, withdrawals, and date of study.
2. Participants: sample size, mean age, age range, sex, ethnicity,
baselineBMD, vitaminDstatus (if available), calciumand vitamin
D intake (if available) and baseline data; inclusion criteria, and
exclusion criteria.
3. Interventions: types of interventions (calcium alone, vitamin
D alone or calcium plus vitamin D); comparison (versus placebo,
or one of the interventions alone). If data are available we will
report other alternative comparisons (i.e. calcium plus vitamin D
versus vitaminDalone, or calcium alone).Wewill report dosage or
type of vitamin D used (ergocalciferol or cholecalciferol), dosage
and type of calcium supplement given, supplementation period
and concomitant medications. We will exclude comparisons with
other interventions, but we will report the type of comparisons
found.
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4. Outcomes: in all cases, we will extract both final and change
from baseline values, but only the final value will be used. If data
are analysed based on an intention-to-treat (ITT) or per-protocol
(PP) sample, only the PP values will be used in the final analysis.
For dichotomous outcomes we will extract the number of events
and number of participants per treatment group. For fractures and
adverse events, we will extract data on both the number of events
and the number of participants sustaining at least one event (for
the analysis we will use the final value).
For continuous outcomes we will extract data as follows.
• Change in BMD: at the total hip and lumbar spine; we will
extract means and standard deviations of the percentage of
change and the number of participants per treatment group (for
the analysis we will use the final change data per treatment
group).
• Quality of life: we will extract means and standard
deviations and number of participants in each treatment group
in units expressed by the specific scale (we will use the final
change data).
Only crude results will be extracted, not adjusted results.
If multiple time points are reported, the information on all time
points will be extracted. We will analyse the effect by short-term
supplementation (< 12 months) and long-term supplementation
(≥ 12 months), for pooling in a meta-analysis.
When hip and vertebral data are available we will conduct analyses
separately by intervention, population and dosage, type of vita-
min D used (ergocalciferol or cholecalciferol) and type of calcium
supplement given.
5. Characteristics of the design of the trial as outlined below in the
Assessment of risk of bias in included studies section. We will note
in the ’Characteristics of included studies’ table if outcome data
were not reported in a usable way and when data were transformed
or estimated from a graph.
6. Notes: The trial funding and conflicts of interest of the trial will
be described.
We will resolve disagreements by consensus or by involving a third
person (PT). One review author (LM-S) will transfer data into
the Review Manager (Review Manager 2014) file. We will dou-
ble-check that data are entered correctly by comparing the data
presented in the systematic review with the study reports.
We will use specific software (Plot Digitizer 2016) to extract data
from graphs or figures. These data will also be extracted in dupli-
cate.
Assessment of risk of bias in included studies
Two review authors (LM-S and PC) will independently assess the
risk of bias for each study using the criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Disagreements will be resolved by discussion or by involving an-
other author (PT). We will assess the risk of bias according to the
following domains.
1. Random sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Blinding of participants and personnel (performance bias).
4. Blinding of outcome assessment (detection bias).
5. Incomplete outcome data (attrition bias).
6. Selective outcome reporting (reporting bias).
We will grade each potential source of bias as high, low or unclear
risk, and provide a quote from the study report together with a
justification for our judgment in the ’Risk of bias’ table. We will
summarize the ’Risk of bias’ judgments across different studies for
each of the domains listed. As well, we will consider the impact of
missing data on key outcomes.
In the case of a lack of important study information, we will con-
tact authors to obtain the information needed, using open-ended
questions. Where the information on risk of bias comes from un-
published data or correspondence with trial lists, we will note this
in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
We will present the figures generated by the ’Risk of bias’ tool to
provide summary assessments of the risk of bias.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as risk ratios or Peto odds ratios
when the outcome is a rare event (approximately less than 10%),
and use 95% confidence intervals (CIs). Continuous data will be
analysed asmean difference (MD) or standardizedmean difference
(SMD), depending on whether the same scale is used to measure
an outcome, and 95% CIs. We will enter data presented as a scale
with a consistent direction of effect across studies.
When different scales are used to measure the same conceptual
outcome (e.g. quality of life), SMDswill be calculated instead,with
corresponding 95%CIs. SMDs will be back-translated to a typical
scale (e.g. 0 to 10 for quality of life) by multiplying the SMD
by a typical among-person standard deviation (e.g. the standard
deviation of one instrument validated from the scale most used in
the trials (Health Assessment Quality, SF-36, etc.)) as per chapter
12 of theCochrane Handbook (Schünemann 2011)
In the ’Effects of interventions’ results section and the ’Comments’
column of the ’Summary of findings’ table, we will provide the
absolute per cent difference, the relative per cent change from
baseline, and the number needed to treat for an additional bene-
ficial (NNTB) or harmful (NNTH) outcome. The NNT will be
provided only when the outcome shows a statistically significant
difference.
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For dichotomous outcomes, the NNTB will be calculated from
the control group event rate and the relative risk using the Visual
Rx NNT calculator (Cates 2008). The NNTB for continuous
measures will be calculated using the Wells calculator.
For dichotomous outcomes, the absolute risk difference will be
calculated using the risk difference statistic in RevMan software
(Review Manager 2014), and the result expressed as a percentage.
The relative per cent change will be calculated as the risk ratio - 1
and expressed as a percentage.
For continuous outcomes, the absolute benefit will be calculated
as the improvement in the intervention group minus the improve-
ment in the control group, in the original units expressed as a per-
centage.
Unit of analysis issues
Where multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons (e.g. calcium
versus placebo and vitamin D versus placebo) are combined in
the same meta-analysis, we will halve the control group to avoid
double-counting. If the same comparisons (e.g. vitamin D versus
different dosages of vitamin D) are combined in the same meta-
analysis, we will separate by dose and comparison group. For the
meta-analysis we will follow the procedures recommended in the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2011).
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data when possible (e.g. when a study is identified as abstract only,
when data are not available for all participants or the data are in a
graphical analysis or adjusted). When this is not possible, and the
missing data are thought to introduce serious bias, we will explore
the impact of including such studies in the overall assessment of
results by conducting a sensitivity analysis. Any assumptions and
imputations to handle missing data will be clearly described and
the effect of imputation will be explored by sensitivity analyses.
For dichotomous outcomes (e.g. number of withdrawals due to
adverse events), the withdrawal rate will be calculated using the
number of patients randomised in the group as the denominator.
For continuous outcomes (e.g. mean change in BMD), we will
calculate the MD or SMD based on the number of patients anal-
ysed at that time point. If the number of patients analysed is not
presented for each time point, the number of randomised patients
in each group at baseline will be used.
Where feasible, we will compute missing standard deviations from
other statistics such as standard errors, CIs or P values, accord-
ing to the methods recommended in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b). If standard
deviations cannot be calculated, we will impute them (e.g. from
other studies in the meta-analysis).
Assessment of heterogeneity
Clinical and methodological diversity will be assessed in terms
of participants, interventions, outcomes and study characteristics
for the included studies to determine whether a meta-analysis is
appropriate. This will be conducted by observing these data from
the data extraction tables. Statistical heterogeneity will be assessed
using the I² and Chi² statistical tests.
As recommended in theCochrane Handbook (Deeks 2011), the
interpretation of an I² value of 0% to 40% might ’not be im-
portant’; 30% to 60% may represent ’moderate’ heterogeneity;
50% to 90% may represent ’substantial’ heterogeneity; and 75%
to 100% represents ’considerable’ heterogeneity. As noted in the
Cochrane Handbook, we will keep in mind that the importance
of I2 depends on: (i) magnitude and direction of effects; and (ii)
strength of evidence for heterogeneity. The Chi² test will be in-
terpreted where a P value ≤ 0.10 indicates evidence of statistical
heterogeneity.
If we identify substantial heterogeneity we will report it and inves-
tigate possible causes by following the recommendations in sec-
tion 9.6 of the Cochrane Handbook (Deeks 2011).
Assessment of reporting biases
We will create and examine a funnel plot to explore possible small
study biases. In interpreting funnel plots, we will examine the
different possible reasons for funnel plot asymmetry as outlined
in section 10.4 of the Cochrane Handbook and relate this to the
results of the review. If we are able to pool more than 10 trials,
we will undertake formal statistical tests to investigate funnel plot
asymmetry, and will follow the recommendations in section 10.4
of the Handbook (Sterne 2011).
To assess outcome reporting bias, we will check trial protocols
against published reports. For studies published after 1 July 2005,
we will screen the Clinical Trial Register at the International Clin-
ical Trials Registry Platform of the World Health Organisation
(apps.who.int/trialssearch) for the a priori trial protocol. We will
evaluate whether selective reporting of outcomes is present.
Data synthesis
Wewill undertakemeta-analyses only where this ismeaningful, i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense.
We will use a random-effects model and perform a sensitivity
analysis with a fixed-effect model.
The primary analysis for our reviews for self-reported outcomes
(e.g. quality of life) will be restricted to trials at low risk of detection
and selection bias.
’Summary of findings’ tables
We will create a ’Summary of findings’ table using the following
outcomes.
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Major outcomes
1. Total hip BMD.
2. Lumbar spine BMD.
3. Quality of life.
4. Vertebral fractures.
5. Non-vertebral fractures.
6. Withdrawals due to adverse events.
7. Serious adverse events (i.e., hospitalizations, or those
resulting in disability or death).
Minor outcomes
1. We will collect data about all adverse events and all harm
reported.
Two people (LM-S and PC) will independently assess the qual-
ity of the evidence. We will use the five GRADE considerations
(study limitations, consistency of effect, imprecision, indirectness
and publication bias) to assess the quality of a body of evidence as
it relates to the studies which contribute data to the meta-analyses
for the prespecified outcomes, and report the quality of evidence
as high, moderate, low, or very low. We will consider the following
criteria for upgrading the quality of evidence, if appropriate: large
effect, dose-response gradient, and plausible confounding effect.
We will use methods and recommendations described in sections
8.5 and 8.7, and chapters 11 and 12, of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011; Schünemann
2011). We will use GRADEpro software to prepare the ’Summary
of findings’ tables (GRADEpro GDT 2016). We will justify all
decisions to down- or up-grade the quality of studies using foot-
notes and we will make comments to aid the reader’s understand-
ing of the review where necessary. We will provide the NNTB or
NNTH, and absolute and relative per cent change in the Com-
ments column of the ’Summary of findings’ table, as described in
the Measures of treatment effect section.
Subgroup analysis and investigation of heterogeneity
We will plan to carry out the following subgroup analyses for all
major outcomes.
1. Dosage groups according to the results reported.We will follow
the recommended dosages given by the Institute of Medicine (
IOM 2011).
Vitamin D:
• ≤ 600 IU
• > 600 IU
Calcium:
• ≤ 1000mg
• > 1000 mg
2. Types of interventions
• Calcium versus placebo
• Vitamin D versus placebo
• Calcium plus vitamin D versus placebo
3. Supplementation time
• Short term < 12 months
• Long term ≥ 12 months
4. Baseline vitamin D levels and baseline dietary calcium intake (if
these are available), following the values established by the Institute
of Medicine (IOM 2011).
• Sufficiency > 30 ng/ml
• Insufficiency 11 to 29 ng/ml
• Deficiency <10 ng/ml
We will use the formal test for subgroup interactions in Review
Manager (Review Manager 2014) and will use caution in the in-
terpretation of subgroup analyses as advised in section 9.6 of the
Handbook (Deeks 2011). The magnitude of the effects we will be
compared between the subgroups by means of assessing the over-
lap of the confidence intervals (CIs) of the summary estimated.
Non-overlap of the CIs indicates statistical significance.
Sensitivity analysis
Weplan to carry out the following sensitivity analyses to investigate
the robustness of the treatment effects.
1. We plan to carry out a sensitivity analysis to investigate the
robustness of the treatment effects, by omitting trials where
unpublished data and/or data imputed from figures or from
other studies were used.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Ovid MEDLINE(R) 1946 to present
Strategy:
1. exp vitamin d/
2. vitamin d.tw.
3. vitamin d2.tw.
4. vitamin d3.tw.
5. exp Ergocalciferols/
6. ergocalciferol$.tw.
7. exp Cholecalciferol/
8. cholecalciferol.tw.
9. hydroxycholecalciferol.tw.
10. calcitriol.tw.
11. dihydroxyvitamin D3.tw.
12. alphacalcidol.tw.
13. Calcium, Dietary/ or Calcium/
14. calcium.tw.
15. Calcium carbonate/
16. Calcium citrate/
17. or/1-16
18. exp Osteoporosis/
19. (bone adj3 loss).tw.
20. (bone adj3 mineral).tw.
21. bone mineral densit$.tw.
22. bmd.tw.
23. bmc.tw.
24. osteop$.tw.
25. Fractures, Bone/
26. exp Osteoporotic Fractures/
27. fractur$.tw.
28. or/18-27
29. randomized controlled trial.pt.
30. controlled clinical trial.pt.
31. randomized.ab.
32. placebo.ab.
33. clinical trials as topic.sh.
34. randomly.ab.
35. trial.ti.
36. or/29-35
37. exp animals/ not humans.sh.
38. 36 not 37
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N O T E S
This protocol is based on a template developed by Cochrane Musculoskeletal’s editorial base.
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